The combinatorial treatment using PARP1 inhibitors and DNA-interacting chemotherapeutic agents was shown to increase the radio sensitivity of the lung tumor [19] and pharmacological PARP1 inhibitor may increase the chemo-sensitivity of NSCLC through PARP1-dependent DNA repair [20]. Here, PARP1 is linked to non-small cell lung carcinoma.